ArticleCirculation. Heart failure2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Circulation. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00094302 (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), which is not on this map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.European heart journal · 2021Trial
- Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.ESC heart failure · 2020Trial
- Can Exercise Training Enhance the Functional Capacity and Diastolic Function in Heart Failure With Preserved Ejection Fraction? A Systematic Review and Meta-analysis in the East Asian Population.International journal of heart failure · 2026Article
- Understanding Geographic Variations in Heart Failure Clinical Trials.Current heart failure reports · 2026Review
- Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction.ESC heart failure · 2026Article
- Demographic disparities in heart failure with preserved ejection fraction.Heart failure reviews · 2025Review
- Coronary microvascular dysfunction and its role in heart failure with preserved ejection fraction for future prevention and treatment.American journal of preventive cardiology · 2025Article
- Racial Differences of Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction.Journal of cardiac failure · 2025Article
- Evaluating the Predictive Accuracy of Socioeconomic Metrics on Heart Failure Risk and Outcomes in Maryland.Cureus · 2024Article
- Myocardial ultrastructure of human heart failure with preserved ejection fraction.Nature cardiovascular research · 2024Article
- Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.Circulation · 2023Article
- A Public Health Critical Race Praxis Informed Congestive Heart Failure Quality Improvement Initiative on Inpatient General Medicine.Journal of general internal medicine · 2023Article
- 20-year trends in multimorbidity by race/ethnicity among hospitalized patient populations in the United States.International journal for equity in health · 2023Article
- Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.Annals of internal medicine · 2023Article
- Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.ESC heart failure · 2023Article
- Pathological mechanism of heart failure with preserved ejection fraction in rats based on iTRAQ technology.PeerJ · 2023Article
- Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Preeclampsia Predicts Risk of Hospitalization for Heart Failure With Preserved Ejection Fraction.Journal of the American College of Cardiology · 2021Article
- Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis.Circulation · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Eldrin F LewisFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.). eflewis@partners.org.
Brian ClaggettFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Amil M ShahFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Jiankang LiuFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Sanjiv J ShahFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Inder AnandFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Eileen O'MearaFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Nancy K SweitzerFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Jean L RouleauFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
James C FangFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Akshay S DesaiFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Tamrat M RettaFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Scott D SolomonFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
John F HeitnerFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Thomas D StamosFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Robin BoineauFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Bertram PittFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Marc A PfefferFrom the Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (E.F.L., B.C., A.M.S., J.L., A.S.D., S.D.S., M.A.P.); Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Veterans Affairs Medical Center Minneapolis, Minnesota (I.A.); University of Minnesota Medical School, Minneapolis (I.A.); Veterans Affairs Medical Center at San Diego, CA (I.A.); Montreal Heart Institute, Quebec, Canada (J.L.R., E.O.); Department of Medicine, Sarver Heart Center, University of Arizona, Tucson (N.K.S.); Division of Cardiology, University of Utah, Salt Lake City (J.C.F.); Department of Medicine, Howard University College of Medicine, Washington, DC (T.M.R.); Division of Cardiology, New York Methodist Hospital, Brooklyn (J.F.H.); Division of Cardiology, University of Illinois at Chicago (T.D.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Brigham and Women's Hospital · US
Funding
Mapping the Progression to HFpEF in the Elderly through Longitudinal Changes in Cardiac FunctionR01HL135008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Amil M Shah · 2017 to 2026
$11.5MSystolic & diastolic dysfunction in heart failure and preserved ejection fractionK08HL116792 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAH, AMIL M · 2013 to 2017
$735kMentoring patient-oriented research in deep phenotyping of cardiac function for heart failure preventionK24HL152008 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAH, AMIL M · 2020 to 2024
$608kNHLBI NIH HHS HHSN268200425207CNHLBI NIH HHS K08 HL116792NHLBI NIH HHS K24 HL152008NHLBI NIH HHS R01 HL135008
Abstract
backgroundBlack patients have been shown to have different baseline characteristics and outcomes compared with nonblack patients in cohort studies. However, few studies have focused on heart failure (HF) with preserved ejection fraction (HFpEF) patients. We aimed to determine the difference in cardiovascular outcomes in black and nonblack patients with HFpEF and to determine the relative efficacy and safety of spironolactone in black and nonblack patients. METHODS AND
resultsPatients with HFpEF, randomized to spironolactone versus placebo in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) in North and South America, were grouped according to self-described black and nonblack race. Black HFpEF patients (n=302) were younger and were more likely to have diabetes mellitus and hypertension than nonblack patients but had similar HFpEF severity. Black patients had higher risk for the primary outcome (hazard ratio [HR], 1.34; 95% confidence interval, 1.06-1.71;
conclusionsBlack patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups. CLINICAL
trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Indexed as
Racial GroupsAgedFemaleHeartHeart FailureHospitalizationHumansHyperkalemiaMaleMiddle AgedMineralocorticoid Receptor AntagonistsSpironolactoneStroke VolumeTreatment OutcomeMineralocorticoid Receptor AntagonistsSpironolactoneechocardiographyheart failurehospitalizationmortalityspironolactone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT00094302ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.